RSV Hospitalisations

Cross-source consensus on RSV Hospitalisations from 1 sources and 5 claims.

1 sources · 5 claims

Benefits

MMR vaccine was associated with reduced RSV-confirmed hospitalisations in children aged 14–23 months. — Systematic review and meta-analysis of the non-specific and broader impact of respiratory vaccines on acute lower respiratory infections in young children
Non-RSV vaccines were associated with protection against RSV hospitalisations in some studies. — Systematic review and meta-analysis of the non-specific and broader impact of respiratory vaccines on acute lower respiratory infections in young children
PCV, childhood seasonal influenza vaccine, and MMR vaccine were each associated with RSV hospitalisation reductions. — Systematic review and meta-analysis of the non-specific and broader impact of respiratory vaccines on acute lower respiratory infections in young children
RSV immunisations are available only in high-income countries despite most global RSV burden occurring in LMICs. — Systematic review and meta-analysis of the non-specific and broader impact of respiratory vaccines on acute lower respiratory infections in young children
Childhood seasonal influenza vaccine showed reduced RSV hospitalisations after controlling for residual confounding with an instrumental variable approach. — Systematic review and meta-analysis of the non-specific and broader impact of respiratory vaccines on acute lower respiratory infections in young children